Private Companies
Neil Markey, CEO of Beckley Retreats, Sits in the Investor Hotseat on November 23rd
Beckley Retreats CEO, Neil Markey, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments. A Captain in the…
Beckley Retreats CEO, Neil Markey, joins the Investor Hotseat to field hot questions from the host, Dustin Robinson of Iter Investments.
A Captain in the US Army Special Operations 2nd Ranger Battalion, Neil was deployed once to Iraq, and twice to Afghanistan. After, as an MBA/MIA master’s student at Columbia University, he suffered from depression and PTSD. This led him to alternative well-being practices and marked the start of a profound healing journey with mindfulness and psychedelics. Prior to Beckley Retreats, Neil worked as the Chief Growth Officer for a $450M private equity portfolio company where he was responsible for all strategy and growth planning. Before that he worked as a consultant at McKinsey & Co, where he co-led the internal mindfulness program.
Will Neil be able to handle the heat in the hotseat?
As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.
If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.
To RSVP to ensure your spot, please fill out the form below.
A Transcription Will Be Available Following the Event
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Law & Regulation1 week ago
Tryp Therapeutics, Exopharm merger approved by shareholders